Regulatory aspects of dissolution for low solubility drug products

Water-Insoluble Drug Formulation, Second Edition

Volumn , Issue , 2008, Pages 101-112

  Sathe, Pradeep ^a   Lionberger, Robert A ^a   Lee, Sau Lawrence ^a   Yu, Lawrence X ^a  

^a FDA Office of Generic Drugs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84055184533     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (25)

1. Yu, L. X., An integrated absorption model for determining causes of poor oral drug absorption, Pharm. Res., 16, 1883, 1999.
2. Lipinski, C. A., Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods, 44, 235, 2000.
3. Pinnamaneni, S., Das, N. G., and Das, S. K., Formulation approaches for orally administered poorly soluble drugs, Pharmazie, 57, 291, 2002.
4. Pouton, C. W., Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system, Eur. J. Pharm. Sci., 29, 278, 2006.
5. Food and Drug Administration CDER, Dissolution testing of immediate release solid oral dosage forms, 1997.
6. Food and Drug Administration CDER, Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system, 2000.
7. Zhang, H. and Yu, L. X., Dissolution testing for solid oral drug products: theoretical consideration, Am. Pharm. Rev., 5, 26-31, September 2004.
8. Brown, C. K. et al., Acceptable analytical practices for dissolution testing of poorly soluble compounds, Pharm. Technol., 28, 56-65, December 2004.
9. Amidon, G. L. et al., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 1995.
10. Yu, L. X. et al., Biopharmaceutics classification system: the scientific basis for biowaiver extension, Pharm. Res., 19, 921, 2002.
11. Yazdanian, M. et al., The high solubility definition of the current FDA Guidance on Biopharmaceutics Classification System may be too strict for acidic drugs, Pharm. Res., 21, 293, 2004.
12. Takano, R. et al., Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test, Pharm. Res., 23, 1144, 2006.
13. Merisko-Liversige, E. et al., Nanosizing: a formulation approach for poorly water-soluble compounds, Eur. J. Pharm. Sci., 18, 113, 2003.
14. Bauer, J. et al., Ritonavir: an extraordinary example of conformational polymorphism, Pharm. Res., 18, 859, 2001.
15. Yu, L., Implementing Quality by Design: OGD initiatives. Advisory Committee for Pharmaceutical Science October 5, 2006. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4241s1-index.htm. Accessed December 1, 2006.
16. Dressman, J. B. and Reppas, C., In vitro in vivo correlations for lipophilic poorly water-soluble drugs, Eur. J. Pharm. Sci., 11, S73, 2000.
17. Noory, C. et al., Steps for development of a dissolution test for sparingly water-soluble drug products, Dissol. Technol., 7, 3, February 2000.
18. Kalantzi, L. et al., Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies, Pharm. Res., 23, 165, 2006.
19. Vertzoni, M. et al., Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds, Eur. J. Pharm. Biopharm., 60, 413, 2005.
20. Nicolaides, E. et al., Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data, Pharm. Res., 16, 1876, 1999.
21. Dressman, J. B., Dissolution Tests-How they relate to drug product performance, FDA, 2005.
22. Mirza. T. et al., Evaluation of dissolution hydrodynamics in the USP, peak and flat-bottom vessels using different solubility drugs, Dissol. Technol., 12, 11-16, February 2005.
23. Yu, L. X., Wang, J. T. and Hussain, A. S., Evaluation of USP apparatus 3 for dissolution testing of immediate-release products, AAPS Pharm. Sci., 4, E1, 2002.
24. FDA Center for Drug Evaluation and Research, Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations, FDA, 1997.
25. Swanepoel, E., Liebenberg, W. and de Villiers, M. M., Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs, Eur. J. Pharm. Biopharm., 55, 345, 2003.